Science Corp Emerges as Neuralink Rival With Vision-Restoring Brain Implant

Science Corporation, the brain-computer interface developer founded by ex-Neuralink president Max Hodak, has raised over $100 million to commercialize neural implants targeting blindness and neurological disorders, positioning the company among a growing field of BCI startups challenging Elon Musk’s dominance in the sector.

The Alameda-based company secured more than $100 million in funding led by Bloomberg-reported convertible note from Khosla Ventures in April 2025, bringing total capital raised to approximately $186 million according to industry sources. The company employs 282 staff as of January 2026, significantly smaller than Neuralink’s operation but focused on near-term clinical deployments.

The funding arrives as Science prepares European regulatory submissions for its PRIMA retinal implant, which restored functional central vision in 84% of trial participants with geographic atrophy, a form of age-related macular degeneration affecting over 5 million people globally, according to results published in The New England Journal of Medicine in October 2025. Patients demonstrated a mean improvement of 25.5 letters—more than five lines—on standardized vision charts, marking what researchers describe as the first successful restoration of reading ability in blind patients.

Technical Differentiation in a Crowded Market

Science Corporation is forgoing traditional metal electrodes in favor of biology-based approaches, including biohybrid interfaces that use living neurons to connect with brain tissue—a departure from Neuralink’s flexible polymer threads and rivals’ rigid silicon arrays. The company is developing biohybrid probe technology using stem cell-derived neurons embedded in electronics and engrafted into the brain, forming new biological connections.

The PRIMA system operates differently. A 2mm × 2mm wireless subretinal implant—30 microns thick, half the width of a human hair—pairs with specialized glasses that project near-infrared light to photovoltaic cells acting as artificial photoreceptors. No batteries. No external cables. The device received FDA Breakthrough status in 2023 and is currently pursuing both FDA and European approval.

Synchron, backed by Bill Gates and Jeff Bezos, received investment from Elon Musk himself in a $75 million round in 2022—an unusual move suggesting tacit acknowledgment that multiple technical approaches may succeed. In 2025, BCI investments reached $856 million in the first half alone, according to HSBC‘s H1 2025 report, led by Neuralink’s $650 million raise, with Science securing $104 million.

Market Positioning and Commercialization Timeline

Science’s medical-first strategy contrasts with Neuralink’s long-term augmentation ambitions. The company has applied for European regulatory approval and hopes to make PRIMA available to patients in 2026, with FDA approval processes underway in the United States. Geographic atrophy affects approximately 1 million Americans, with 160,000 new cases annually and 8 million patients worldwide—a defined addressable market absent competing treatments.

The neurotechnology market is expected to reach $29.74 billion by 2030, growing at a 13.53% compound annual growth rate, according to Mordor Intelligence. The brain-computer interface implant segment specifically is projected to expand from $351.3 million in 2025 to $1.18 billion by 2035, with invasive BCIs commanding premium positioning despite surgical complexity.

Beyond PRIMA, Science operates the Science BCI Ecosystem, a full-stack platform bundling tools for developing BCI therapies, allowing partners like Swiss firm Neurosoft Bioelectronics to plug into ready-to-use infrastructure, shaving tens of millions in development costs. The company manufactures Axon neural probes, SciFi headstages, and Synapse communication protocols from its North Carolina microfabrication facility—vertical integration that could drive recurring revenue as the ecosystem scales.

Competitive Landscape and Strategic Risks

Neuralink, valued around $9 billion following its June 2025 fundraise, dominates media attention and has implanted three patients, demonstrating cursor control and gaming applications. Precision Neuroscience, founded by another ex-Neuralink executive, closed $102 million in December 2024 and reported record-setting 4,096-electrode human recordings with its surface-based Layer 7 interface.

The principal risk: Industry founders estimate $150-200 million to prove out high-sophistication BCIs with bidirectional recording and stimulation. Science’s current capital may prove insufficient for multi-indication expansion. The company is developing next-generation glasses and working to miniaturize PRIMA’s 378 electrodes to hair-width dimensions without enlarging the implant—engineering challenges requiring sustained R&D investment.

Meanwhile, Sam Altman’s Merge Labs raised $250 million at an $850 million valuation in late 2025, pursuing ultrasound-based brain interfaces enhanced by gene therapy that could read and stimulate neural activity without surgical implantation—a non-invasive approach that, if successful, could undermine the value proposition of surgical BCIs entirely.

What to Watch

European CE mark approval timing will signal whether Science can establish first-mover advantage in vision restoration before better-funded competitors pivot from research to commercialization. FDA Breakthrough Device designation typically accelerates review, but closed-loop spinal cord stimulators took until 2024 for FDA clearance despite adaptive therapy demonstrating 84% of patients achieving ≥50% pain reduction—a benchmark suggesting 2027-2028 US availability is more realistic than the company’s stated timeline.

Reimbursement negotiations will prove critical. Payers view reduced downstream costs—lower addiction rates, fewer hospitalizations—as justification for neurotechnology coverage, but geographic atrophy lacks the opioid crisis urgency that drove pain management adoption. Pricing strategy must balance recouping $200+ million development costs against demonstrating cost-effectiveness versus standard-of-care observation.

Partnership announcements beyond Neurosoft would validate the BCI Ecosystem business model. If Science can become the “Android” of neural interfaces—providing infrastructure while others build applications—the company’s strategic value extends beyond its proprietary devices. Conversely, failure to attract third-party developers suggests the ecosystem remains a secondary bet to PRIMA’s clinical success.

Watch for Series B or C announcements in Q2 2026. The $856 million deployed in H1 2025 represented a record pace, but macroeconomic headwinds and Neuralink’s market dominance may constrain follow-on capital. Science’s ability to secure $200+ million at a premium valuation—implying $1+ billion pre-money based on comparable late-stage medical device rounds—will determine whether the biohybrid technology thesis can scale beyond vision into cognition and mobility applications Hodak founded the company to address.